ClinicalTrialsFinder

EGFR Mutation-negative and ALK Rearrangement-negative Clinical Trials in Guangzhou, Guangdong

1 recruitingGuangzhou, Guangdong, China

Showing 1–1 of 1 trials

Recruiting

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLCEGFR Mutation-negative and ALK Rearrangement-negativeEastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2+2 more
Guangdong Association of Clinical Trials265 enrolled1 locationNCT07696832